NCT03157128
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1
Drug Category: Tyrosine-Kinase Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 12 Years and older (Child, Adult), Senior)
Location of Metastases: 
Additional Notes: Breast cancer patients will not be eligible for the expansion cohort
Exclusions: Symptomatic or unstable CNS metastases
https://ClinicalTrials.gov/show/NCT03157128